Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient

Objective: To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen. Case Summary: A 3-year-old girl who had been diagnosed with PAN was referred to our ho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Annals of pharmacotherapy 2007-05, Vol.41 (5), p.885-890
Hauptverfasser: Gonzalez-Fernandez, Maria Angeles, Garcia-Consuegra, Julia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 890
container_issue 5
container_start_page 885
container_title The Annals of pharmacotherapy
container_volume 41
creator Gonzalez-Fernandez, Maria Angeles
Garcia-Consuegra, Julia
description Objective: To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen. Case Summary: A 3-year-old girl who had been diagnosed with PAN was referred to our hospital from another region. With conventional treatment of high doses of a corticosteroid and cyclophosphamide, her condition resolved. Six months later, our patient had a relapse that required hospital admission. In this second hospital stay, some cutaneous lesions evolved into digital necrosis. Off-label therapeutic alternatives, including a single dose (2 g/kg) of intravenous immunoglobulin (IVIG), intravenous iloprost 2 ng/kg/min over 6 h for 5 days and, approximately 4 wk later, oral bosentan 37.25 mg twice daily for 4 wk followed by 62.5 mg twice daily for 8 wk, were added to the conventional regimen to treat the serious cutaneous manifestations. Her fingers improved very slowly, and she was discharged on gradually tapered doses of oral corticosteroids, bosentan, and monthly pulsed injections of cyclophosphamide. The digital necrosis and other cutaneous lesions had resolved completely 6 months after the second discharge. Discussion: The dosages of IVIG and iloprost were based on those used for PAN, Raynaud's phenomenon, and digital necrosis in children. The use of bosentan for vasculitis had not been reported in children before the treatment of our patient, so its dosage was based on that used to produce vasodilation in children with pulmonary hypertension. Conclusions: Digital necrosis and cutaneous manifestations not resolved with conventional PAN treatment improved within 5 days with iloprost and 12 weeks with bosentan.
doi_str_mv 10.1345/aph.1H637
format Article
fullrecord <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1345_aph_1H637</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1H637</sage_id><sourcerecordid>10.1345_aph.1H637</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-521b70046e36c0d91b1f600b9f1a3c01eae9e78bd659ef7169c716ff7e78f8db3</originalsourceid><addsrcrecordid>eNptkMtKAzEUhoMoVqsLX0CyUXAx9WQuycxSilqh2CJ1Hc7MJG3KdKYkqaVvb2oL3bg5Nz7-Ax8hdwwGLEmzZ1wvBmzEE3FGrliWxhGPBZyHGThEEOfQI9fOLQGgYHFxSXpMpJDlcXxFJtOu2aH1yhpvHP3s6s4h_VLOOI-tp76jw679Ua03XYsNnVmFfhVWalqKdKpqg96aik7Rm3C-IRcaG6duj71Pvt9eZ8NRNJ68fwxfxlGViNRHWcxKAZBylfAK6oKVTHOAstAMkwqYQlUokZc1zwqlBeNFFYrWIhx1XpdJnzwdcivbOWeVlmtrVmh3koHcS5FBivyTEtj7A7velCtVn8ijhQA8HAF0FTbaYlsZd-LyXPAi3gc9HjiHcyWX3cYGJe7fj8fAhZkvtsYq6VbYNOE_k9vtNmUyk3meJb9XC4Qa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient</title><source>MEDLINE</source><source>SAGE Journals</source><creator>Gonzalez-Fernandez, Maria Angeles ; Garcia-Consuegra, Julia</creator><creatorcontrib>Gonzalez-Fernandez, Maria Angeles ; Garcia-Consuegra, Julia</creatorcontrib><description>Objective: To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen. Case Summary: A 3-year-old girl who had been diagnosed with PAN was referred to our hospital from another region. With conventional treatment of high doses of a corticosteroid and cyclophosphamide, her condition resolved. Six months later, our patient had a relapse that required hospital admission. In this second hospital stay, some cutaneous lesions evolved into digital necrosis. Off-label therapeutic alternatives, including a single dose (2 g/kg) of intravenous immunoglobulin (IVIG), intravenous iloprost 2 ng/kg/min over 6 h for 5 days and, approximately 4 wk later, oral bosentan 37.25 mg twice daily for 4 wk followed by 62.5 mg twice daily for 8 wk, were added to the conventional regimen to treat the serious cutaneous manifestations. Her fingers improved very slowly, and she was discharged on gradually tapered doses of oral corticosteroids, bosentan, and monthly pulsed injections of cyclophosphamide. The digital necrosis and other cutaneous lesions had resolved completely 6 months after the second discharge. Discussion: The dosages of IVIG and iloprost were based on those used for PAN, Raynaud's phenomenon, and digital necrosis in children. The use of bosentan for vasculitis had not been reported in children before the treatment of our patient, so its dosage was based on that used to produce vasodilation in children with pulmonary hypertension. Conclusions: Digital necrosis and cutaneous manifestations not resolved with conventional PAN treatment improved within 5 days with iloprost and 12 weeks with bosentan.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1H637</identifier><identifier>PMID: 17405822</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Los Angeles, CA: Harvey Whitney Books</publisher><subject>Anti-Inflammatory Agents - therapeutic use ; Antihypertensive Agents - therapeutic use ; Arthralgia - etiology ; Azathioprine - therapeutic use ; Biological and medical sciences ; Child, Preschool ; Cyclophosphamide - therapeutic use ; Female ; Fever - etiology ; Humans ; Iloprost - therapeutic use ; Immunoglobulins, Intravenous - therapeutic use ; Immunosuppressive Agents - therapeutic use ; Medical sciences ; Methylprednisolone - therapeutic use ; Pharmacology. Drug treatments ; Polyarteritis Nodosa - drug therapy ; Polyarteritis Nodosa - pathology ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Sulfonamides - therapeutic use ; Vasodilator Agents - therapeutic use</subject><ispartof>The Annals of pharmacotherapy, 2007-05, Vol.41 (5), p.885-890</ispartof><rights>2007 Harvey Whitney Books Company</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-521b70046e36c0d91b1f600b9f1a3c01eae9e78bd659ef7169c716ff7e78f8db3</citedby><cites>FETCH-LOGICAL-c374t-521b70046e36c0d91b1f600b9f1a3c01eae9e78bd659ef7169c716ff7e78f8db3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1345/aph.1H637$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1345/aph.1H637$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18876927$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17405822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gonzalez-Fernandez, Maria Angeles</creatorcontrib><creatorcontrib>Garcia-Consuegra, Julia</creatorcontrib><title>Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>Objective: To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen. Case Summary: A 3-year-old girl who had been diagnosed with PAN was referred to our hospital from another region. With conventional treatment of high doses of a corticosteroid and cyclophosphamide, her condition resolved. Six months later, our patient had a relapse that required hospital admission. In this second hospital stay, some cutaneous lesions evolved into digital necrosis. Off-label therapeutic alternatives, including a single dose (2 g/kg) of intravenous immunoglobulin (IVIG), intravenous iloprost 2 ng/kg/min over 6 h for 5 days and, approximately 4 wk later, oral bosentan 37.25 mg twice daily for 4 wk followed by 62.5 mg twice daily for 8 wk, were added to the conventional regimen to treat the serious cutaneous manifestations. Her fingers improved very slowly, and she was discharged on gradually tapered doses of oral corticosteroids, bosentan, and monthly pulsed injections of cyclophosphamide. The digital necrosis and other cutaneous lesions had resolved completely 6 months after the second discharge. Discussion: The dosages of IVIG and iloprost were based on those used for PAN, Raynaud's phenomenon, and digital necrosis in children. The use of bosentan for vasculitis had not been reported in children before the treatment of our patient, so its dosage was based on that used to produce vasodilation in children with pulmonary hypertension. Conclusions: Digital necrosis and cutaneous manifestations not resolved with conventional PAN treatment improved within 5 days with iloprost and 12 weeks with bosentan.</description><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Arthralgia - etiology</subject><subject>Azathioprine - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child, Preschool</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Female</subject><subject>Fever - etiology</subject><subject>Humans</subject><subject>Iloprost - therapeutic use</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Medical sciences</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Polyarteritis Nodosa - drug therapy</subject><subject>Polyarteritis Nodosa - pathology</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Sulfonamides - therapeutic use</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkMtKAzEUhoMoVqsLX0CyUXAx9WQuycxSilqh2CJ1Hc7MJG3KdKYkqaVvb2oL3bg5Nz7-Ax8hdwwGLEmzZ1wvBmzEE3FGrliWxhGPBZyHGThEEOfQI9fOLQGgYHFxSXpMpJDlcXxFJtOu2aH1yhpvHP3s6s4h_VLOOI-tp76jw679Ua03XYsNnVmFfhVWalqKdKpqg96aik7Rm3C-IRcaG6duj71Pvt9eZ8NRNJ68fwxfxlGViNRHWcxKAZBylfAK6oKVTHOAstAMkwqYQlUokZc1zwqlBeNFFYrWIhx1XpdJnzwdcivbOWeVlmtrVmh3koHcS5FBivyTEtj7A7velCtVn8ijhQA8HAF0FTbaYlsZd-LyXPAi3gc9HjiHcyWX3cYGJe7fj8fAhZkvtsYq6VbYNOE_k9vtNmUyk3meJb9XC4Qa</recordid><startdate>20070501</startdate><enddate>20070501</enddate><creator>Gonzalez-Fernandez, Maria Angeles</creator><creator>Garcia-Consuegra, Julia</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20070501</creationdate><title>Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient</title><author>Gonzalez-Fernandez, Maria Angeles ; Garcia-Consuegra, Julia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-521b70046e36c0d91b1f600b9f1a3c01eae9e78bd659ef7169c716ff7e78f8db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Arthralgia - etiology</topic><topic>Azathioprine - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child, Preschool</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Female</topic><topic>Fever - etiology</topic><topic>Humans</topic><topic>Iloprost - therapeutic use</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Medical sciences</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Polyarteritis Nodosa - drug therapy</topic><topic>Polyarteritis Nodosa - pathology</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Sulfonamides - therapeutic use</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonzalez-Fernandez, Maria Angeles</creatorcontrib><creatorcontrib>Garcia-Consuegra, Julia</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonzalez-Fernandez, Maria Angeles</au><au>Garcia-Consuegra, Julia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2007-05-01</date><risdate>2007</risdate><volume>41</volume><issue>5</issue><spage>885</spage><epage>890</epage><pages>885-890</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>Objective: To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen. Case Summary: A 3-year-old girl who had been diagnosed with PAN was referred to our hospital from another region. With conventional treatment of high doses of a corticosteroid and cyclophosphamide, her condition resolved. Six months later, our patient had a relapse that required hospital admission. In this second hospital stay, some cutaneous lesions evolved into digital necrosis. Off-label therapeutic alternatives, including a single dose (2 g/kg) of intravenous immunoglobulin (IVIG), intravenous iloprost 2 ng/kg/min over 6 h for 5 days and, approximately 4 wk later, oral bosentan 37.25 mg twice daily for 4 wk followed by 62.5 mg twice daily for 8 wk, were added to the conventional regimen to treat the serious cutaneous manifestations. Her fingers improved very slowly, and she was discharged on gradually tapered doses of oral corticosteroids, bosentan, and monthly pulsed injections of cyclophosphamide. The digital necrosis and other cutaneous lesions had resolved completely 6 months after the second discharge. Discussion: The dosages of IVIG and iloprost were based on those used for PAN, Raynaud's phenomenon, and digital necrosis in children. The use of bosentan for vasculitis had not been reported in children before the treatment of our patient, so its dosage was based on that used to produce vasodilation in children with pulmonary hypertension. Conclusions: Digital necrosis and cutaneous manifestations not resolved with conventional PAN treatment improved within 5 days with iloprost and 12 weeks with bosentan.</abstract><cop>Los Angeles, CA</cop><pub>Harvey Whitney Books</pub><pmid>17405822</pmid><doi>10.1345/aph.1H637</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1060-0280
ispartof The Annals of pharmacotherapy, 2007-05, Vol.41 (5), p.885-890
issn 1060-0280
1542-6270
language eng
recordid cdi_crossref_primary_10_1345_aph_1H637
source MEDLINE; SAGE Journals
subjects Anti-Inflammatory Agents - therapeutic use
Antihypertensive Agents - therapeutic use
Arthralgia - etiology
Azathioprine - therapeutic use
Biological and medical sciences
Child, Preschool
Cyclophosphamide - therapeutic use
Female
Fever - etiology
Humans
Iloprost - therapeutic use
Immunoglobulins, Intravenous - therapeutic use
Immunosuppressive Agents - therapeutic use
Medical sciences
Methylprednisolone - therapeutic use
Pharmacology. Drug treatments
Polyarteritis Nodosa - drug therapy
Polyarteritis Nodosa - pathology
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Sulfonamides - therapeutic use
Vasodilator Agents - therapeutic use
title Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A46%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polyarteritis%20Nodosa%20Resistant%20to%20Conventional%20Treatment%20in%20a%20Pediatric%20Patient&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Gonzalez-Fernandez,%20Maria%20Angeles&rft.date=2007-05-01&rft.volume=41&rft.issue=5&rft.spage=885&rft.epage=890&rft.pages=885-890&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.1H637&rft_dat=%3Csage_cross%3E10.1345_aph.1H637%3C/sage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17405822&rft_sage_id=10.1345_aph.1H637&rfr_iscdi=true